75 mg and hyoscine 0.3 mg at 8.45 am and anaesthesia was induced one hour later with thiopentone 375 mg. After suxamethonium 50 mg he was intubated easily, with no evidence of masseter spasm, and anaesthesia was maintained with a mixture of oxygen 1.0 llmin, nitrous oxide 1.0 llmin and halothane 1.5-2.0%. Intraoperative monitoring comprised a pulse monitor and a manual sphygmomanometer. The operation proceeded uneventfully for forty minutes until just prior to its completion, at 10.35, when the patient developed a tachycardia of 140 beats per minute. The halothane was ceased and 100% oxygen administered; the patient's skin temperature felt normal and he was not cyanosed.
At extubation, the patient was observed to be slightly cyanosed when breathing room air, but this improved with 100% oxygen. At 10.45 he was admitted to the recovery room, where his pulse rate was 140 beats per minute and blood pressure 80/50 mmHg, and as his skin temperature had risen considerably, a rectal temperature probe was inserted and read 40.3°C. He was slightly centrally cyanosed with an FI02 of 1.0, and he had developed a tachypnoea and rigidity of his thighs. Cooling procedures were commenced immediately (axillary ice-packs, tepid sponging and fanning) and from 10.55 to 11.00 an initial dose of 120 mg (2 mg/kg) of dantrolene was administered intravenously.
Arterial blood gas estimation at 11.00 revealed: pH 7.19, PC02 51 mmHg, P02 99 mmHg, HCO} 19 mmol/l and Base Excess -9.3 mmol/l (FI02 1.0). Within twenty minutes of the first dose of dantrolene, his temperature had risen to 41.4 °C and there had been no improvement in his clinical condition, and accordingly a further dose of 120 mg was given. Following this he was given sodium bicarbonate 100 mmol, and glucose 50 g and soluble insulin 25U intravenously as his serum potassium at 11.00 was 6.4 mmolll.
At 11.40, despite having received 4 mg/kg of dantrolene, his high temperature persisted at 41.0°C, and as there had been no diminution of his tachycardia, tachypnoea or muscle rigidity, a further 2 mglkg of dantrolene was given. Over the ensuing fifteen minutes a marked improvement in his clinical status occurred, and within thirty minutes of the third dose of dantrolene his temperature had subsided to 37.3°C, his pulse and respiratory rates were returning to normal and there had been almost complete resolution of his muscle rigidity. Arterial blood gases obtained at 11.45 revealed: pH 7.32 PC02 49 mmHg, P02 197 mmHg, HCO} 25 mmol/1 and Base Excess -1.3 mmoll1 (FI02 1.0).
The patient was transferred to the Intensive Care Unit where he developed transient myoglobinaemia and myglobinuria. A diuresis was maintained with intravenous crystalloids. Serum potassium at 2.00 p.m. was 4.0 mmolll and thereafter remained within normal limits, and clotting profile and DIC studies were normal. His serum CPK rose from 571 lUll during the crisis to 2, 929 lUll at 12.15 p.m., and peaked at 33, 720 lUll later the same day (range 25-170 lUll). His recovery was otherwise uneventful and he was discharged home after family counselling and after preliminary arrangements for in vitro muscle testing had been made. Random CPK levels performed on the members of his family revealed elevated readings in two of four siblings and one parent; to date only one sibling (with an elevated CPK) has undergone muscle biopsy and in vitro testing, and this was strongly positive, confirming the diagnosis of MH susceptibility (personal communication, R.F.W. Moulds, Royal Melbourne Hospital). All members of the DISCUSSION The severity ofMH crises may depend upon a variety offactors such as the chemical nature and concentration of the volatile anaesthetic agent used,3,4 the duration of anaesthesia and the degree of susceptibility of the patient. 1 The intensity is usually more pronounced when the volatile agent is used in combination with suxamethonium. 3 There are several points of interest exhibited by this case. Our patient displayed a normal response to suxamethonium, and although one cannot accurately predict MH susceptibility solely on the sign of trismus, especially in children,S abnormal muscular rigidity and in particular masseter spasm after suxamethonium may herald the onset of an MH crisis. 6 ,7 The presentation of MH may not occur for several hours after exposure to anaesthetic drugs, 8 and in the case presented above, tachycardia and cyanosis developed approximately fifty minutes after the administration of suxamethonium and the commencement of halothane anaesthesia. In a multicentre study conducted in 1982,9 seven of eight patients with unequivocal MH presented at least fifty minutes after induction.
The most interesting feature of this case was the dose of dantrolene required to attenuate the crisis, a total of 6 mg/kg. The initial dose recommended in the management of an acute crisis of MH, based on responses observed in awake human beings,1O is 2.4 mg/kg, and a mean dose of 2.5 mg/kg was sufficient to reverse MH reactions in the above-mentioned multicentre study.9 In our case, however, despite early administration an initial dose of 2 mg/kg produced no improvement, and approximately ten minutes after a further 2 mg/kg, the only observable change in the patient's condition was a fall in temperature of 0.4°c.
The Malignant Hyperpyrexia Association of the U.S.A. has stated in its guidelines that the response to dantrolene should begin to occur in minutes, and if not, more drug should be administered as necessary, titrated against the progression of the clinical signs. l How long one elects to wait for a dose of dantrolene to have its affect when faced with a fulminant MH crisis will depend upon the clinical setting and the decision of those managing the case, as well as the number of staff recruitable for the somewhat laborious task of the drug's reconstitution and the latter's availability.
The precise number of vials of dantrolene which should be to hand in the operating theatre is of practical importance. In relating the dose of dantrolene to the survival from a MH reaction in 117 cases, Britt found that all patients (18) who received an early initial dose of at least 6 mg/kg survived; 11 of the 99 who received less than 6 mg/kg died. 11 Apart from other factors determining survival in this context, the obvious disparity between this dose and the recommended initial dose of2.0-2.5 mg/kg is considerable.
The Australian Society of Anaesthetists states in its policy on dantrolene that a dose of 2-3 mg/kg should be sufficient to treat an acute MH reaction, and recommends twelve vials (240 mg) as a reasonable starting supply, which would be equivalent to a dose of 2.5 mg/kg for a 96 kg patient. The policy also recommends that serious consideration be given to the ready availability of further supplies from nearby institutions within a reasonable period of time. 12 A total dose of 6 mg/kg for a 96 kg patient would represent a further seventeen vials. Therefore, in those more remote hospitals where ready access to supplementary supplies may not exist, it would seem advisable that seventeen additional vials be immediately available.
